Low-intervention clinical trials occupy a unique position within the European Clinical Trials Regulation. Designed to simplify certain studies involving already authorized medicines, these trials were expected to facilitate pragmatic research and accelerate academic and real-world studies.
However, several years after the implementation of EU Regulation 536/2014, low-intervention clinical trials remain relatively underused across Europe.
Low-Intervention Clinical Trials: A Definition Still Poorly Understood
EU Regulation 536/2014 introduced a specific category of clinical trials known as low-intervention clinical trials.
According to the “Agence nationale de sécurité du médicament et des produits de santé”, a study falls into this category when several conditions are met:
- The investigational medicinal product already has a marketing authorization
- The medicine is used in accordance with its marketing authorization or supported by published scientific evidence
- Additional diagnostic or monitoring procedures involve only minimal additional risk or burden for participants
ANSM FAQ on Regulation 536/2014:
https://ansm.sante.fr/documents/reference/faq-entree-en-vigueur-du-reglement-europeen-sur-les-essais-cliniques-de-medicaments-ndeg-536-2014
The official regulation also defines this category in Article 2:
https://www.doctrine.fr/l/texts/eu/reglements/EULEG09FA3A34824F0AAAD8E6/articles/EULEGARTI43D55DEB6A679CEBF0D0
In theory, this framework was intended to create a more proportionate regulatory approach aligned with the actual level of patient risk.
Why Are Low-Intervention Clinical Trials Still Underused?
Despite this simplification logic, low-intervention clinical trials remain underexploited by many sponsors.
One major difficulty lies in the interpretation of the concept of “minimal risk.” Depending on the Member State, Competent Authority, or Ethics Committee, certain additional procedures may still be considered beyond the acceptable low-risk framework.
This heterogeneity creates significant regulatory uncertainty, particularly for academic sponsors.
Another limitation is that, although Regulation 536/2014 provides some simplifications, low-intervention clinical trials still require submission through the Clinical Trials Information System portal and remain subject to many administrative requirements applicable to traditional clinical trials.
CTIS User Handbook:
https://www.ema.europa.eu/en/documents/other/ctis-user-handbook-investigators_en.pdf
For many hospital or university research teams, the operational complexity therefore remains relatively high compared to traditional observational studies.
The lack of European harmonization is also a major obstacle. A protocol considered a low-intervention clinical trial in one country may be assessed differently in another Member State, complicating multinational studies.
Low-Intervention Clinical Trials and Real-World Evidence
Low-intervention clinical trials are becoming increasingly relevant in the current context of Real-World Evidence (RWE) development.
They may be particularly suitable for:
- Comparisons of existing therapeutic strategies
- Pragmatic multicenter studies
- Academic research in routine clinical practice
- Drug repurposing studies
- Certain post-marketing evaluations
The European Medicines Agency actively encourages the growing use of real-world data in medicine evaluation.
EMA page on Real-World Evidence:
https://www.ema.europa.eu/en/human-regulatory/research-development/data-medicines-regulation/real-world-evidence
Low-intervention clinical trials may therefore help generate complementary evidence that is closer to real-life treatment conditions, particularly in patient populations that are often underrepresented in traditional randomized controlled trials.
A Strategic Challenge for European Clinical Research Attractiveness
The development of low-intervention clinical trials is also becoming a strategic issue for the attractiveness of European clinical research.
In a context of intense international competition, European authorities are seeking to accelerate pragmatic clinical research while maintaining high standards of participant safety.
The European Commission has repeatedly emphasized the need to make Europe more attractive for multinational clinical research.
European Commission page on Clinical Trials:
https://health.ec.europa.eu/medicinal-products/clinical-trials_en
However, several conditions still appear necessary to fully support the development of low-intervention clinical trials:
- Harmonizing regulatory interpretation across Member States
- Clarifying Competent Authority expectations
- Reducing certain administrative burdens
- Providing additional support to academic sponsors using CTIS
- Strengthening investigator training on this specific category of trials
A Category of Clinical Trials Likely to Expand?
With the increasing importance of pragmatic approaches and real-world evidence, low-intervention clinical trials may progressively play a larger role in European clinical research.
Their initial promise remains highly attractive: generating robust clinical data with a level of regulatory burden more proportionate to the actual risks faced by participants.
In a context of economic pressure and growing demand for faster clinical evaluations, low-intervention clinical trials could ultimately become a key tool for balancing innovation, patient safety, and regulatory simplification.
